The influx of novel therapies is expanding treatment options for patients with cancer, but distance, infrastructure, and ...
In “Immunotherapy in MSI-High and dMMR mCRC,” Dr. Strickler discusses how immune checkpoint inhibition has reshaped treatment ...
Real-world evidence indicates that longer biologic dosing intervals are associated with higher persistence and fewer ...
Dr. Haumschild compares SGLT2 inhibitors and GLP-1 receptor agonists as evidence in both classes keeps evolving. He acknowledges GLP-1s carry real budget impact that payers cannot ...
Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a true hepatitis B cure. It is the first therapy approved with a primary ...
Not every patient who carries Clostridioides difficile ( C diff) gets sick, and distinguishing colonization from true ...
Karolinska Institutet’s Antoine Créon, MD, explains how alert fatigue, workflow, and center-level variation may have limited ...
Permanent standard time is the only option that ends biannual clock changes while keeping the body aligned with the sun, ...
Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling ...
The FDA on Friday approved a subcutaneous (SC) induction regimen for risankizumab-rzaa (Skyrizi; AbbVie) in adults with moderately to severely active Crohn disease, giving patients the option to begin ...
Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.
As cancer treatments improve and patients are living longer, answering the question of who takes charge of care once active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results